Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market Pharmaceutical Investing
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis Geography
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer Market News
